Professional Documents
Culture Documents
Tranexamic Acid For Traumatic Brain Injury
Tranexamic Acid For Traumatic Brain Injury
Shahriar Zehtabchi, MD a,
Samah G. Abdel Baki,MDa,
Louise Falzon, BA, Daniel K.
Nishijima, MD
Introduction
an estimated 1.4 million emergency department (ED)
Trauma
visits
275000 hospitalizations
Brain Injury
52000 deaths each year
progressive intracranial bleeding, cerebral edema,
increased intracranial pressure, subsequent cerebral
Secondary
Brain Injury
ischemia
worsened by posttraumatic coagulopathy
Antifibrinolyt
ic agent
tranexamic
acid (TXA) Does administration of TXA (intervention) compared to
placebo (comparison) improve patients' outcomes such
as reduction inmortality, neurologic function, and
Outcome hemorrhage progression (outcome)?
Methods
Study Design :
Randomized controlled trials (RCTs) or quasi-RCTs
Literature Search :
Predesigned search strategy developed by an expert medical
librarian (LF)
MEDLINE (1946 to March 2014),
EMBASE (1980 to March 2014),
CINAHL (1981 to March 2014) and
the Cochrane Library were searched.
In addition we were look for relevant presented abstracts and
contacted the experts to solicit information about possible
ongoing, unpublished studies.
Methods
Data extraction
Data from the identified studies were abstracted independently by 2 of the
authors (SZ and SGA) using a standardized form.
Quality assessment
Grading quality of evidence and strength of recommendations criteria to assess the
quality of the included trial and rate the level of evidence
Mechanism
1. TXA, as an antifibrinolytic agent,
may limit fibrinolysis and thus ICH 2.TXA may inhibit the effect of
progression. Fibrinolysis is common tissue plasminogen activator,
in TBI and has been shown to be a which plays a role in perilesional
strong independent predictor of ICH edema
progression.
Limitations
There was some heterogeneity between
identified studies, particularly in the
inclusion criteria
The included studies did not account
for patients receiving anticoagulants
or antiplatelet agents.
The mechanism of injury could be a
confounder that needs to be examined
in future trials.
The meta-analysiswas performedwith
only 2 trials.
Conclusion
Pooled results from the 2 RCTs demonstrated
statistically significant reduction in ICH progression with
TXA and a non statistically significant improvement of
clinical outcomes in ED patients with TBI.